DE60218842D1 - Orale verabreichung von parathyroidhormon und calcitonin - Google Patents

Orale verabreichung von parathyroidhormon und calcitonin

Info

Publication number
DE60218842D1
DE60218842D1 DE60218842T DE60218842T DE60218842D1 DE 60218842 D1 DE60218842 D1 DE 60218842D1 DE 60218842 T DE60218842 T DE 60218842T DE 60218842 T DE60218842 T DE 60218842T DE 60218842 D1 DE60218842 D1 DE 60218842D1
Authority
DE
Germany
Prior art keywords
calcitonin
oral administration
parathyroid hormone
pth
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60218842T
Other languages
English (en)
Other versions
DE60218842T2 (de
Inventor
Joseph M Ault
Moise Azria
Simon David Bateman
James F Mcleod
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23136525&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60218842(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of DE60218842D1 publication Critical patent/DE60218842D1/de
Application granted granted Critical
Publication of DE60218842T2 publication Critical patent/DE60218842T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
DE60218842T 2001-06-01 2002-05-31 Orale verabreichung von parathyroidhormon und calcitonin Expired - Lifetime DE60218842T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29516901P 2001-06-01 2001-06-01
US295169P 2001-06-01
PCT/EP2002/006017 WO2002098453A2 (en) 2001-06-01 2002-05-31 Orally administering parathyroid hormone and calcitonin

Publications (2)

Publication Number Publication Date
DE60218842D1 true DE60218842D1 (de) 2007-04-26
DE60218842T2 DE60218842T2 (de) 2007-12-20

Family

ID=23136525

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60218842T Expired - Lifetime DE60218842T2 (de) 2001-06-01 2002-05-31 Orale verabreichung von parathyroidhormon und calcitonin

Country Status (25)

Country Link
US (2) US20040186050A1 (de)
EP (1) EP1397156B1 (de)
JP (2) JP5073153B2 (de)
KR (3) KR20090116836A (de)
CN (2) CN101837120A (de)
AT (1) ATE356631T1 (de)
AU (2) AU2002344371B2 (de)
BR (1) BRPI0209748B1 (de)
CA (1) CA2446929C (de)
CO (1) CO5540323A2 (de)
CZ (1) CZ307145B6 (de)
DE (1) DE60218842T2 (de)
EC (1) ECSP034858A (de)
ES (1) ES2282436T3 (de)
HU (1) HU229613B1 (de)
IL (2) IL158777A0 (de)
MX (1) MXPA03011027A (de)
NO (1) NO330093B1 (de)
NZ (1) NZ529439A (de)
PL (1) PL211976B1 (de)
PT (1) PT1397156E (de)
RU (1) RU2300392C2 (de)
SK (1) SK287697B6 (de)
WO (1) WO2002098453A2 (de)
ZA (1) ZA200308625B (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ529439A (en) 2001-06-01 2005-11-25 Novartis Ag Method for orally administering parathyroid hormone (PTH)
EP1420827B8 (de) * 2001-08-17 2009-12-23 Novartis AG 5-cnac zur oralen verabreichung von parathormonfragmenten
US20050054557A1 (en) * 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
PE20100241A1 (es) 2005-09-19 2010-04-16 Emisphere Tech Inc Formas cristalinas de la sal di-sodio del acido n-(5-clorosaliciloil)-8-aminocaprilico
GB0522566D0 (en) 2005-11-04 2005-12-14 Novartis Ag Organic compounds
CA2628945A1 (en) * 2005-11-10 2007-05-24 Board Of Control Of Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
KR20140053419A (ko) * 2005-11-17 2014-05-07 노파르티스 아게 약제학적 조성물
MX2010004716A (es) 2007-11-02 2010-12-17 Emisphere Tech Inc Metodo para tratar la deficiencia de vitamina b12.
CN104857505A (zh) * 2008-08-18 2015-08-26 安特拉贝欧有限公司 用于口服给予蛋白质的方法和组合物
RU2494755C2 (ru) 2008-08-18 2013-10-10 Интера Био Лтд. Способы и композиции для перорального введения белков
WO2011071480A1 (en) 2009-12-07 2011-06-16 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
WO2012130193A1 (en) 2011-03-31 2012-10-04 Zentiva, K.S. Non-covalent soluble complexes of teriparatide with polysaccharides and a dosage form of teriparatide for oral administration
CN104800564A (zh) * 2015-04-02 2015-07-29 中国人民解放军济南军区总医院 一种治疗血虚不荣型甲状旁腺功能减退症的中药组合物
KR101796604B1 (ko) * 2016-08-30 2017-11-10 목포대학교 산학협력단 위장관 흡수증진제를 함유하는 부갑상선 호르몬의 경구 투여 제형
KR102115353B1 (ko) * 2019-05-17 2020-05-26 주식회사 노브메타파마 Chp(사이클로-히스프로) 및 부갑상선 호르몬을 포함하는 골 손실 질환의 예방, 개선 또는 치료용 조성물

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4692433A (en) * 1983-10-12 1987-09-08 The Regents Of The University Of California Method and composition for regulating serum calcium levels of mammals
US5364840A (en) * 1989-12-05 1994-11-15 Vical, Inc. Synthetic calcitonin peptides
US5118667A (en) * 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
AU6268894A (en) * 1993-02-22 1994-09-14 Alza Corporation Compositions for oral delivery of active agents
US5866536A (en) * 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
US5723577A (en) 1995-07-13 1998-03-03 Biomeasure Inc. Analogs of parathyroid hormone
US5955574A (en) * 1995-07-13 1999-09-21 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A. Analogs of parathyroid hormone
DK1093819T3 (da) 1997-02-07 2006-09-11 Emisphere Tech Inc Forbindelse og præparat til tilförsel af aktive midler
SE9702401D0 (sv) 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
DE19915272A1 (de) * 1999-04-03 2000-10-05 Vetter & Co Apotheker Spritze für medizinische Zwecke
WO2000059863A1 (en) * 1999-04-05 2000-10-12 Emisphere Technologies, Inc. Disodium salts, monohydrates, and ethanol solvates
AU1189301A (en) 1999-10-29 2001-05-14 Eli Lilly And Company A pharmaceutical composition having high cell membrane permeability
US7049283B2 (en) * 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
NZ529439A (en) 2001-06-01 2005-11-25 Novartis Ag Method for orally administering parathyroid hormone (PTH)
EP1420827B8 (de) * 2001-08-17 2009-12-23 Novartis AG 5-cnac zur oralen verabreichung von parathormonfragmenten
US7318925B2 (en) * 2003-08-08 2008-01-15 Amgen Fremont, Inc. Methods of use for antibodies against parathyroid hormone

Also Published As

Publication number Publication date
CA2446929C (en) 2013-04-09
SK14752003A3 (sk) 2004-06-08
HUP0400120A2 (hu) 2005-04-28
BRPI0209748B1 (pt) 2015-11-24
CA2446929A1 (en) 2002-12-12
CN101837120A (zh) 2010-09-22
PL364089A1 (en) 2004-12-13
EP1397156B1 (de) 2007-03-14
KR101320817B1 (ko) 2013-10-21
NZ529439A (en) 2005-11-25
KR20040007617A (ko) 2004-01-24
US8153587B2 (en) 2012-04-10
JP2010189423A (ja) 2010-09-02
MXPA03011027A (es) 2004-03-19
KR20090116836A (ko) 2009-11-11
EP1397156A2 (de) 2004-03-17
NO330093B1 (no) 2011-02-14
PT1397156E (pt) 2007-05-31
RU2003136733A (ru) 2005-05-20
WO2002098453A2 (en) 2002-12-12
AU2006225157B2 (en) 2009-04-23
HU229613B1 (en) 2014-03-28
ECSP034858A (es) 2004-01-28
ATE356631T1 (de) 2007-04-15
JP2005500277A (ja) 2005-01-06
CZ20033232A3 (cs) 2004-06-16
CO5540323A2 (es) 2005-07-29
BR0209748A (pt) 2004-07-27
PL211976B1 (pl) 2012-07-31
NO20035133L (no) 2003-11-18
HUP0400120A3 (en) 2012-09-28
NO20035133D0 (no) 2003-11-18
ZA200308625B (en) 2004-07-13
RU2300392C2 (ru) 2007-06-10
SK287697B6 (sk) 2011-06-06
IL158777A0 (en) 2004-05-12
US20040186050A1 (en) 2004-09-23
KR20120065429A (ko) 2012-06-20
AU2006225157A1 (en) 2006-10-19
US20080119411A1 (en) 2008-05-22
ES2282436T3 (es) 2007-10-16
WO2002098453A3 (en) 2003-07-31
CN1512892A (zh) 2004-07-14
DE60218842T2 (de) 2007-12-20
IL158777A (en) 2012-06-28
JP5073153B2 (ja) 2012-11-14
CZ307145B6 (cs) 2018-02-07
AU2002344371B2 (en) 2006-06-29

Similar Documents

Publication Publication Date Title
ATE356631T1 (de) Orale verabreichung von parathyroidhormon und calcitonin
AR033639A1 (es) Uso de hormonas paratiroideas para preparar medicamentos para reducir el riesgo de fracturas oseas vertebrales o no vertebrales en seres humanos con riesgo de padecer o que padecen osteoporosis
CY1109661T1 (el) 5-cnac ως παραγοντας για χορηγηση απο το στομα τμηματων παραθορμονης
SE0202857D0 (sv) Method and compositions for preventing hormone induced adverse effects
DE60205749D1 (de) Oral anzuwendende arzneizusammensetzungen mit gesteuerter wirkstoffabgabe
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
GT199800177A (es) Combinacion eficaz para el tratamiento de la impotencia .
SE0102993D0 (sv) New self emulsifying drug delivery system
NO20026055L (no) Farmasöytiske komponenter innbefattende humant paratyreoideahormon og farmasöytiske sammenstninger for nasal administrering inneholdendekomponentene
ATE353224T1 (de) Abgabeeinrichtung für eine zusammensetzung einer pharmazeutisch wirksamen substanz
AU2001267887A1 (en) Medicinal components comprising human parathyroid hormone and medicinal compositions for nasal administration containing the components
AR040737A1 (es) Administracion oral de calcitonina
CA2385755A1 (en) Prevention of colorectal cancer
WO2001066102A3 (en) Oral dosage form for administration of the combination of tegafur, uracil, folinic acid, and oxaliplatin and method of using the same
FR2839450B1 (fr) Preparation medicamenteuse notamment pour le traitement des hernies discales
IT1265647B1 (it) Composizione farmaceutiche topiche per le allergie respiratorie
AR023398A1 (es) Terapia para melanomas
ECSP003419A (es) Terapia para melanomas
BR0012467A (pt) Agente terapêutico para hipercalcemia resistente à droga

Legal Events

Date Code Title Description
8363 Opposition against the patent
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN